We previously showed that the pan-ErbB inhibitor dacomitinib was superior to lapatinib in preventing PCa progression [23]; however, dacomitinib has greater side effects; hence, we investigated whether lapatinib efficacy could be improved with another low toxic drug. Here, EGFR is linked to posterior cortical atrophy.